Mural Oncology (MURA)
1.12
-0.11 (-8.94%)
At close: Apr 04, 2025, 3:59 PM
1.14
1.79%
After-hours: Apr 04, 2025, 05:35 PM EDT
-8.94% (1D)
| Bid | 1.11 |
| Market Cap | 19.3M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -7.58 |
| PE Ratio (ttm) | -0.15 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Ask | 1.29 |
| Volume | 532,001 |
| Avg. Volume (20D) | 267,624 |
| Open | 1.20 |
| Previous Close | 1.23 |
| Day's Range | 1.12 - 1.25 |
| 52-Week Range | 1.11 - 4.74 |
| Beta | 5.32 |
About MURA
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was inco...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2023
Employees 116
Stock Exchange NASDAQ
Ticker Symbol MURA
Website https://www.muraloncology.com
Analyst Forecast
According to 4 analyst ratings, the average rating for MURA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 1239.29% from the latest price.
Stock Forecasts1 week ago
-61.62%
Mural Oncology shares are trading lower after the ...
Unlock content with
Pro Subscription
6 months ago
+5%
Mural Oncology shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy and announced an $18 price target.
